MDGL Q2 2018 Earnings — Madrigal Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

MDGLMadrigal Pharmaceuticals, Inc.

$10B

Q2 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$24,000

Operating Income

-$8M

Net Income

-$6M

EPS (Diluted)

$-0.45

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$5M

Free Cash Flow

-$5M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$492M

Total Liabilities

$5M

Stockholders' Equity

$486M

Cash & Equivalents

$265M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$24,000	-$8,000	-200.0%
Operating Income	-$8M	-$8M	+7.3%
Net Income	-$6M	-$8M	+22.6%